Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
jeudi, octobre 22
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Nektar Therapeutics
NKTR
NASDAQ
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$38.27
-0.95
-2.42%
Dern. MÀJ: Oct 21, 4:49 PM
$38.05
-1.17
-2.98%
Get Report
Aperçu
Actualités
Prévisions de résultats
Événements
Objectifs de cours
Données financières
Sentiment
Actionnariat
Comparer
Options
Rapport sur les stocks
Privacy Manager
Nektar Therapeutics Financials
Nektar Therapeutics (NKTR) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Nektar Therapeutics Q2 EPS $(1.23) Beats $(2.00) Estimate, Sales $10.131M Miss $10.425M Estimate
Benzinga Newsdesk
PRO
Nektar Therapeutics Q1 EPS $(1.82) Misses $(1.62) Estimate, Sales $10.860M Beat $10.636M Estimate
Nektar Therapeutics (NASDAQ:NKTR) reported quarterly losses of $(1.82) per share which missed the analyst consensus estimate of $(1.62) by 12.35 percent. This is a 49.72 percent increase over losses of $(3.62) per share
Benzinga Newsdesk
PRO
Nektar Therapeutics Q4 EPS $(1.78) Beats $(2.59) Estimate, Sales $21.807M Beat $10.404M Estimate
Nektar Therapeutics (NASDAQ:NKTR) reported quarterly losses of $(1.78) per share which beat the analyst consensus estimate of $(2.59) by 31.27 percent. This is a 442.31 percent decrease over earnings of $0.52 per share
Benzinga Newsdesk
Earnings Scheduled For March 12, 2026
Benzinga Insights
PRO
Nektar Therapeutics Q3 EPS $(1.87) Beats $(2.69) Estimate, Sales $11.790M Beat $10.048M Estimate
Nektar Therapeutics (NASDAQ:NKTR) reported quarterly losses of $(1.87) per share which beat the analyst consensus estimate of $(2.69) by 30.35 percent. This is a 29.7 percent increase over losses of $(2.66) per share
Benzinga Newsdesk
Earnings Scheduled For November 6, 2025
Benzinga Insights
